CCR4拮抗剂抑制T细胞向肿瘤微环境的转运。
CCR4 Antagonists Inhibit T Trafficking into the Tumor Microenvironment.
作者信息
Ketcham John M, Marshall Lisa A, Talay Oezcan
机构信息
FLX Bio, Inc., 561 Eccles Avenue, South San Francisco, California 94080, United States.
出版信息
ACS Med Chem Lett. 2018 Sep 10;9(10):953-955. doi: 10.1021/acsmedchemlett.8b00351. eCollection 2018 Oct 11.
Abstract
Recruitment of naturally occurring suppressive CD4, CD25, and FOXP3 regulatory T cells (T) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human T express CCR4 and can be recruited to the TME through the C-C chemokines CCL17 and CCL22. We have recently developed a series of potent, orally bioavailable small molecule antagonists of CCR4 that can block recruitment of T into the TME.
摘要
将天然存在的具有抑制作用的CD4、CD25和FOXP3调节性T细胞（T细胞）募集到肿瘤微环境（TME）中，可能会削弱接受免疫肿瘤学（IO）药物治疗患者的抗肿瘤反应。人T细胞表达CCR4，并可通过C-C趋化因子CCL17和CCL22被募集到TME中。我们最近开发了一系列强效的、口服生物可利用的CCR4小分子拮抗剂，它们可以阻止T细胞募集到TME中。
相似文献
1
CCR4 Antagonists Inhibit T Trafficking into the Tumor Microenvironment.CCR4拮抗剂抑制T细胞向肿瘤微环境的转运。
ACS Med Chem Lett. 2018 Sep 10;9(10):953-955. doi: 10.1021/acsmedchemlett.8b00351. eCollection 2018 Oct 11.
2
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T Trafficking into the Tumor Microenvironment.发现一种强效和选择性的 CCR4 拮抗剂，可抑制 T 细胞向肿瘤微环境中的迁移。
J Med Chem. 2019 Jul 11;62(13):6190-6213. doi: 10.1021/acs.jmedchem.9b00506. Epub 2019 Jul 1.
3
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.新型哌啶基氮杂环丁烷类化合物作为强效和选择性的 CCR4 拮抗剂，单药或与检查点抑制剂联合使用可引发抗肿瘤反应。
J Med Chem. 2020 Aug 13;63(15):8584-8607. doi: 10.1021/acs.jmedchem.0c00988. Epub 2020 Jul 28.
4
Tumors establish resistance to immunotherapy by regulating T recruitment via CCR4.肿瘤通过调节 T 细胞募集来建立对免疫疗法的抵抗，这是通过 CCR4 实现的。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-000764.
5
Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.鼻窦鳞状细胞癌和鼻内翻性乳头状瘤中调节性T细胞的频率、抑制能力、募集及诱导机制
PLoS One. 2015 May 28;10(5):e0126463. doi: 10.1371/journal.pone.0126463. eCollection 2015.
6
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.CD4(+)CD25(+)调节性T细胞独特的趋化反应谱及趋化因子受体CCR4和CCR8的特异性表达。
J Exp Med. 2001 Sep 17;194(6):847-53. doi: 10.1084/jem.194.6.847.
7
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.肿瘤微环境中的CCL17和CCL22趋化因子与胃癌中Foxp3 +调节性T细胞的积聚有关。
Int J Cancer. 2008 May 15;122(10):2286-93. doi: 10.1002/ijc.23392.
8
The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors.大多数人类外周血CD4+CD25高表达Foxp3+调节性T细胞带有功能性皮肤归巢受体。
J Immunol. 2006 Oct 1;177(7):4488-94. doi: 10.4049/jimmunol.177.7.4488.
9
Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.尽管淋巴器官中CD25⁺Foxp3⁺调节性T细胞耗竭，但Ret转基因小鼠仍发生皮肤黑色素瘤。
J Immunol. 2009 Nov 15;183(10):6330-7. doi: 10.4049/jimmunol.0900609. Epub 2009 Oct 19.
10
Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells.在诱导趋化因子受体CCR4脱敏及人Th2细胞内化过程中，CCL22比CCL17更具优势。
Eur J Immunol. 2004 Jan;34(1):231-40. doi: 10.1002/eji.200324429.
引用本文的文献
1
Analyses of single-cell RNA sequencing uncover the role of intratumoral Helicobacter pylori in shaping tumor progression and immunity in gastric cancer.单细胞RNA测序分析揭示了肿瘤内幽门螺杆菌在塑造胃癌肿瘤进展和免疫中的作用。
Cancer Immunol Immunother. 2025 May 24;74(7):218. doi: 10.1007/s00262-025-04048-6.
2
Determinants of resistance and response to melanoma therapy.黑色素瘤治疗耐药和应答的决定因素。
Nat Cancer. 2024 Jul;5(7):964-982. doi: 10.1038/s43018-024-00794-1. Epub 2024 Jul 17.
3
Listeria-vectored cervical cancer vaccine candidate strains reduce MDSCs via the JAK-STAT signaling pathway.李斯特菌载体宫颈癌候选疫苗株通过 JAK-STAT 信号通路减少髓系来源抑制细胞。
BMC Biol. 2024 Apr 19;22(1):88. doi: 10.1186/s12915-024-01876-3.
4
Targeting T regulatory (T) cells in immunotherapy-resistant cancers.在免疫治疗耐药性癌症中靶向调节性T细胞。
Cancer Drug Resist. 2024 Jan 12;7:2. doi: 10.20517/cdr.2023.46. eCollection 2024.
5
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.用于癌症治疗的单克隆抗体的治疗靶点：现状与新进展
Biomedicines. 2023 Jul 24;11(7):2086. doi: 10.3390/biomedicines11072086.
6
CCR4 Blockade Diminishes Intratumoral Macrophage Recruitment and Augments Survival of Syngeneic Pancreatic Cancer-Bearing Mice.CCR4阻断可减少同基因胰腺癌荷瘤小鼠瘤内巨噬细胞募集并延长其生存期。
Biomedicines. 2023 May 24;11(6):1517. doi: 10.3390/biomedicines11061517.
7
The Effect of Lung Resection for NSCLC on Circulating Immune Cells: A Pilot Study.非小细胞肺癌肺切除术后对循环免疫细胞的影响：一项初步研究。
Curr Oncol. 2023 May 17;30(5):5116-5134. doi: 10.3390/curroncol30050387.
8
Chemokine Homeostasis in Healthy Volunteers and during Pancreatic and Colorectal Tumor Growth in Murine Models.健康志愿者以及小鼠模型中胰腺和结肠直肠肿瘤生长期间的趋化因子稳态
Curr Issues Mol Biol. 2022 Oct 18;44(10):4987-4999. doi: 10.3390/cimb44100339.
9
Targeting regulatory T cells for immunotherapy in melanoma.靶向调节性T细胞用于黑色素瘤的免疫治疗。
Mol Biomed. 2021;2(1):11. doi: 10.1186/s43556-021-00038-z. Epub 2021 Apr 19.
10
Small Molecule CCR4 Antagonists Protect Mice from Infection and Allergy.小分子 CCR4 拮抗剂保护小鼠免受 感染和过敏。
Biomolecules. 2021 Feb 25;11(3):351. doi: 10.3390/biom11030351.
本文引用的文献
1
Small molecule immuno-oncology therapeutic agents.小分子免疫肿瘤治疗药物。
Bioorg Med Chem Lett. 2018 Feb 1;28(3):319-329. doi: 10.1016/j.bmcl.2017.12.044. Epub 2017 Dec 20.
2
Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists.AZD-2098和AZD-1678这两种强效且具有生物利用度的CCR4受体拮抗剂的发现。
ACS Med Chem Lett. 2017 Sep 1;8(9):981-986. doi: 10.1021/acsmedchemlett.7b00315. eCollection 2017 Sep 14.
3
Introduction to checkpoint inhibitors and cancer immunotherapy.检查点抑制剂与癌症免疫疗法简介。
Immunol Rev. 2017 Mar;276(1):5-8. doi: 10.1111/imr.12531.
4
Targeting chemokine receptors in disease--a case study of CCR4.针对疾病中的趋化因子受体——以CCR4为例的个案研究
Eur J Pharmacol. 2015 Sep 15;763(Pt B):169-77. doi: 10.1016/j.ejphar.2015.05.018. Epub 2015 May 14.
5
Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists.趋化因子受体CCR4的内化可由正构和变构受体拮抗剂诱发。
Eur J Pharmacol. 2014 Apr 15;729(100):75-85. doi: 10.1016/j.ejphar.2014.02.007. Epub 2014 Feb 15.
6
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.抗 CCR4 mAb 选择性耗竭效应型 FoxP3+CD4+调节性 T 细胞，在人体内引发抗肿瘤免疫应答。
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50. doi: 10.1073/pnas.1316796110. Epub 2013 Oct 14.
7
Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study.CC趋化因子受体4拮抗剂GSK2239633在健康男性受试者中的安全性、耐受性、药代动力学和药效学：一项开放标签研究和一项随机研究的结果
BMC Pharmacol Toxicol. 2013 Feb 28;14:14. doi: 10.1186/2050-6511-14-14.
8
Regulatory T cells in tumor immunity.肿瘤免疫中的调节性 T 细胞。
Int J Cancer. 2010 Aug 15;127(4):759-67. doi: 10.1002/ijc.25429.
9
CCR4 as a novel molecular target for immunotherapy of cancer.CCR4作为癌症免疫治疗的新型分子靶点。
Cancer Sci. 2006 Nov;97(11):1139-46. doi: 10.1111/j.1349-7006.2006.00307.x. Epub 2006 Sep 5.
Zotero 插件